OsteoMed Marketing New Hammertoe Remedy
Biloine W. Young • Mon, July 29th, 2013
The FDA has granted 510(k) clearance to OsteoMed, LLC to market its ExtremiFuse device for the correction of hammertoe deformities. Company officials estimate that approximately 60 million people suffer from this toe deformity and 550,000 surgeries are performed annually to correct it. Hammertoe occurs most frequently in the second, third and fourth toes, according to a company official.
OsteoMed is offering ExtremiFuse in both a straight and 10 degree solution.Officials say that these self-drilling, threaded implants provide for easy insertion. They can be placed without using a drill and the shape and design reduce the force need to fully place the implant. ExtremiFuse is OsteoMed’s latest product release and officials state that it complements the firm’s existing comprehensive lower extremity product portfolio.
“Our commitment to providing improved patient outcomes through the design, manufacture and service of high quality, innovative and cost-effective surgical products continues with this exciting new product offering,” stated David Kelly, vice president of OsteoMed’s Small Bone Orthopedic Division. The company was founded in 1990 and is located in Addison, Texas.